Brind.

Lipocine is developing LPCN 1154 for Postpartum Depression (PPD) treatment, with trials seeking FDA approval. The development involves expertise from NIH and affiliated centers like Northwell Health.

1 report, 0 independent Updated Jun 23

AI-generated analysis. Brind wrote this summary from the reports listed below. It can be wrong. Each section says how much you can rely on it, and the sources are linked so you can check.

What happened

SpeculativeNo independent reporting found

Who's involved

What this event is mainly about

Lipocine (United States)FDA

Keep exploring

The entities involved

Lipocine (United States)
company in Salt Lake City, United States

Nothing else this week.
FDA
- Generic medicine services are seeking approval for launch from the FDA.Mon 17:49
- A company is seeking FDA feedback on its NEO212 program, with a meeting scheduled at the FDA's White Oak campus.Mon 14:56

Related events

Clinical research studies for new indications were reported by the FDA concerning a company identified as Cpt.Aug 12

Coverage

Newest first; wire copies grouped

Jun 23Unknown outlet